1


                                                                    EXHIBIT 23.1


                              Accountants' Consent


The Board of Directors and Stockholders
Anthra Pharmaceuticals, Inc.:


We consent to the use of our report included herein and to the references to
our firm under the headings "Selected Consolidated Financial Data" and 
"Experts" in the prospectus.



Our report dated August 12, 1998 contains an explanatory paragraph that states 
that the Company has suffered recurring losses from operations, has a net 
capital deficiency and has insufficient working capital to fund its current 
operating requirements, which raise substantial doubt about its ability to 
continue as a going concern. The consolidated financial statements do not 
include any adjustments that might result from the outcome of that uncertainty.



                                     /s/ KPMG PEAT MARWICK LLP

Princeton, New Jersey

October 21, 1998